This broad research space has been garnering significant attention.!--h2>
The focus of this GEN BioMarket Trends report is the expanding field of single-cell analysis (SCA), which is a broad and amorphous space. Highlights of the report:
Biological heterogeneity between cells is now becoming recognized as a key contributor to disease as is believed to be the case in cells derived from primary tumors that may possess alterations enabling them to see distant metastases.
In order therefore to understand and treat disease at the fundamental level, cell-cell differences within a population must be analyzed and appreciated—this opens up the realm of SCA, which is gathering significant attention.
In this report we provide an update on CTCs as a special case of SCA wherein some clinical utility of CTC measurements has been demonstrated.
Much work remains, however, in the realm of single-cell sequencing and single-cell genomics, and the industry is just beginning to recognize the importance of SCA.
More reports will follow over the coming months analyzing different facets of the SCA marketplace.
Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at [email protected].